Variable reduction in Norrin signaling activity caused by novel mutations in FZD4 identified in patients with familial exudative vitreoretinopathy

Tian Tian, Xiang Zhang, Qi Zhang, Peiquan Zhao
(The first two authors contributed equally to this study.)

Department of Ophthalmology, Xinhua Hospital, Affiliated to Medicine School of Shanghai Jiaotong University, Kongjiang Road, Shanghai, China

Purpose: To identify novel mutations in FZD4 and to investigate their pathogenicity in a cohort of Chinese patients with familial exudative vitreoretinopathy (FEVR).

Methods: Next-generation sequencing was performed in patients with a clinical diagnosis of FEVR. Wide-field angiography was performed in probands and family members if available. Clinical data were collected from patient charts. The effect of the mutations in FZD4 on its biologic activity in the Norrin/β-catenin signaling pathway was analyzed with the luciferase reporter assay.

Results: Four novel mutations in FZD4 (c.1188_1192del/p.F396fs, c.1220delC/p.A407Vfs*24, c.905G>A/p.C302Y, c.1325T>A/p.V442E) were identified in four unrelated families. The mutations were not detected in 200 healthy individuals. The variability of the ocular phenotypes was not only observed in the probands and parents harboring the same mutation but also between two eyes in one individual. All four novel mutations introduced reduction in luciferase activity. Compared with the wild-type, the FZD4 level of the four mutants also decreased variably.

Conclusions: Four novel mutations in FZD4 were identified in Chinese patients with FEVR. No correlation in the reduced luciferase activity and the ocular phenotype was observed in this study. This study further emphasized the complexity of the FEVR-causing machinery.

Familial exudative vitreoretinopathy (FEVR) is a hereditary ocular disorder characterized by impaired development of the retinal vessels and various secondary complications, including retinal folds and retinal detachments [1]. The clinical phenotypes of FEVR vary from asymptomatic to complete blindness, even within the same family [2-4].

To date, approximately 50% of the clinically identified patients with FEVR have been found to be associated with the following five causative genes: NDP (OMIM 300658, X-linked) [5], FZD4 (OMIM 604579, dominant) [6], LRP5 (OMIM 603506, dominant and recessive) [7,8], TSPAN12 (OMIM 613138, dominant and recessive) [9-11], and ZNF408 (NCBI 79797, dominant) [12]. Recently, Robitaille et al. first identified mutations in KIF11 (OMIM 148760) in patients with FEVR [13].

The gene FZD4 encodes a member of the frizzled and smoothened superfamily of seven-transmembrane-domain cell-surface proteins that can function as receptors for wingless (Wnt) proteins [14]. In the best studied “canonical” Wnt signaling pathway, Wnt ligand exerts its activity through binding to the receptors of FZD4 and LRP5, leading to stabilization of intracellular β-catenin, which forms a complex with members of the lymphoid enhancer factor/T-cell factor (LEF/TCF) family of transcription factors and activates downstream target genes [15].

However, the pathogenic mechanism of FEVR is complicated. Until now, no clear genotype–phenotype correlation has been identified. In addition, the pathogenicity of missense mutations is not clear, and thus, genetic counseling cannot be provided. In this study, we identified four novel mutations in FZD4 with next-generation sequencing in a cohort of 621 patients with FEVR. We performed the SuperTopFlash (STF) reporter assay to demonstrate these four novel mutations in FZD4 induced variable reduction in the Norrin signaling activity. This study further emphasized the complexity of the FEVR-causing machinery.

METHODS

Participants and clinical data collection: The study was approved by the Ethics Committee of Xinhua Hospital and was performed in accordance with the tenets of the
Declaration of Helsinki. Informed written consent was obtained from the parents or guardians of each participant because they were minor children. Between January 2010 and October 2017, 621 clinically diagnosed patients with FEVR were collected in our clinic. All participants were born full-term. Patients with a clinical diagnosis of FEVR routinely underwent a complete ophthalmologic evaluation, including visual acuity measurement (if available), anterior segment examination, ultrasound examination, indirect ophthalmoscopy with a 28D lens, fundus examination using a Retcam (Clarity Medical Systems, Pleasanton, CA) or Optos 200Tx (Optos, Inc., Marlborough, MA) imaging device, and wide-field fluorescein angiography (if available) of the ora serrate using a Retcam under anesthesia or a Spectralis HRA2 (Heidelberg Engineering GmbH, Heidelberg, Germany) based on the patients’ age. Additionally, wild-field fluorescein angiography was routinely performed in patients’ direct family members, primarily the parents and siblings (if any) who could tolerate fluorescein sodium using the Spectralis HRA2 (Heidelberg Engineering GmbH) in the clinic when available. Optos imaging was performed in family members who could not tolerate fluorescein sodium.

**Genetic testing:** Next-generation sequencing (NGS) was performed with MyGenostics (Baltimore, MD). Briefly, peripheral blood was drawn from each proband and his or her direct family members, and the genomic DNA was extracted and fragmented. Briefly, peripheral blood was drawn from each proband and his or her direct family members using a whole blood DNA extraction kit (BioTeke, Beijing, China). Venous blood in EDTA vacutainers was stored in 4 °C and processed within 24 h after blood drawn. Genomic DNA samples were extracted blood DNA extraction kit following manufacturer’s instruction (Biotek). Illumina adapters were added to the fragments, and the samples were size-selected for the 350 to 400 bp products. This pool of DNA fragments was amplified using PCR and allowed to hybridize with DNA capture probes that were specifically designed for the targeted genes. PCR working conditions are as following: initial denature temperature 95 °C for 3 min, followed by 33 cycles of reaction: template denature at 95 °C for 15 s, annealing for 15 s at 59 °C and extension at 72 °C for 20 s. A final step of 7 min reaction extension at 72 °C was applied to fill in the gaps of PCR product. The captured DNA fragments were eluted, amplified again, and subjected to NGS using an Illumina HiSeq 2000 (Illumina, Inc., San Diego, CA). A

**Figure 1.** Chromatograms and pedigrees of four families with familial exudative vitreoretinopathy. A, B: In family A, the c.1188_1192del (p.F396fs) was identified in a 4-year-old boy and his affected father. C, D: In family B, we identified the c.1220delC (p.A407Vfs*24) mutation in a 3-year-old boy and his affected father. E, F: In family C, the c.905G>A (p.C302Y) mutation was identified in a 3-year-old boy and his affected father. G, H: In family D, we identified the c.1325T>A (p.V442E) mutation in a 2-year-old boy and his affected father. In the pedigrees, M sign represents a variant; WT represents a normal allele; arrows, probands; squares, males; circles, females; filled symbols, affected individuals; open symbols, unaffected individuals.
Figure 2. Fundus and angiographic images of family B with familiar exudative vitreoretinopathy. A, B: Color photographs and an angiographic image of the proband show a disappeared anterior chamber in the right eye and aberrant vessels with an avascular area in the peripheral retina of the left eye. A control picture of a normal anterior chamber from another individual is provided as reference (bottom right corner in A). C–F: His mutation-carrying father is asymptomatic with a peripheral avascular area and abnormal vessels in the left eye. G, H: His mother has normal retinal vasculature demonstrated with angiography.
custom Genetic Pediatric Retinal Diseases Panel based on targeted exome capture technology was used and covered the following 21 genes:  *ABCB6* (OMIM 605452),  *GDF6* (OMIM 601147),  *LRP5* (OMIM 603506),  *RS1* (OMIM 312700),  *SOX2* (OMIM 184429),  *TENM3* (OMIM 610083),  *VSX2* (OMIM 142993),  *FZD4* (OMIM 604579),  *IKBKG* (OMIM 300248),  *NDP* (OMIM 300658),  *SALL2* (OMIM 602219),  *STRA6* (OMIM 610745),  *TSPAN12* (OMIM 613138),  *YAPI* (OMIM 606608),  *GDF3* (OMIM 610522),  *KIF11* (OMIM 148760),  *PAX6* (OMIM 607108),  *SHH* (OMIM 600725),  *TBX1* (OMIM 602054),  *TUBA8* (OMIM 605742), and  *ZNF408* (NCBI 79797). The pipeline that was used to filter the data and to generate the final result is shown in the supplemental material.

**Plasmids:**  *LRP5*,  *FZD4*, and *Norrin* plasmids were generously provided by Dr. Jeremy Nathans of Johns Hopkins University.
Figure 4. Fundus and angiographic images of family C with familiar exudative vitreoretinopathy. A–D: Fundus examination and angiography reveal extremely asymmetric ocular phenotypes of the proband. The right fundus shows the peripheral avascular area and abnormal vessels. However, the left fundus manifests as similar to Norrie disease with choroidal atrophy. E, F: Retinal vascular anomalous formation and an area of the avascular retina are observed in his affected father. G, H: His mother has normal retinal vasculature demonstrated with angiography.
All mutant plasmids were generated using a site-directed mutagenesis kit (Stratagene, La Jolla, CA). The expression plasmids containing the FLAG tag were first verified with DNA sequencing, and then the expression was checked with transfection using a Lipofectamine 2000 Transfection Reagent (Invitrogen, Carlsbad, CA).

Luciferase assays: The STF reporter, in which firefly luciferase was driven by seven LEF/TCF consensus binding sites, was kindly gifted by Dr. Jeremy Nathans. The reporter plasmid was stably infected into human embryonic kidney (HEK) 293 cells (short tandem repeat analysis shown in the Supplementary Data) as previously reported to generate the STF cell line [16]. In 24-well plates, STF cells were transfected with 700 ng DNA with 1.1 μl Lipofectamine 2000 Transfection Reagent (Invitrogen). The DNA mix contained 200 ng of Norrin, 200 ng of LRP5, 100 ng of pSV-β-galactosidase control vector, and 200 ng of FZD4 (wild-type or mutation).
Forty-eight hours after transfection, the cells were harvested and washed twice with PBS (1X; 120 mM NaCl, 20 mM KCl, 10 mM NaPO₄, 5 mM KPO₄, pH 7.4). Luciferase activities were measured with a dual-luciferase assay kit (Promega, Madison, WI). Reporter activity was normalized to the coexpressed β-galactosidase activity in each well. Each test was performed in triplicate. The reporter assay was repeated three times, and a representative result was obtained.

**Cell culture:** HEK 293 cells were cultured in Dulbecco’s modified essential medium (DMEM, ATCC, Manassas, VA; Hyclone; Appendix 1) supplemented with 10% fetal bovine serum (Invitrogen) and 1% antibiotics (penicillin/streptomycin; Invitrogen).

**Immunoblotting and antibodies:** The transfected cells were lysed in radioimmune precipitation assay buffer (50 mM Tris-HCl (pH 7.4), 400 mM NaCl, 1 mM EDTA, 1% Nonidet P40, 0.1% sodium dodecyl sulfate (SDS), 1% sodium deoxycholate, and a mixture of protease inhibitors) and cleared with centrifugation. Cleared cell lysates were boiled at 100 °C for 10 min. Proteins were resolved with SDS–polyacrylamide gel electrophoresis (PAGE) and transferred onto polyvinylidene fluoride (PVDF) membranes (Millipore, Darmstadt, Germany), followed by immunoblotting using corresponding antibodies according to the manufacturer’s instructions. Immunoblots were analyzed using the LAS-4000 system (Fujifilm) according to the manufacturer’s instructions. Antibodies against FLAG M2 were purchased from Sigma (Saint Louis, MO) and actin from Cell Signaling Technology (Beverly, MA).

**Statistical analysis:** Statistical analyses were performed with a two-tailed unpaired Student t test. All data shown represent the results obtained from triplicate independent experiments with a standard error of the mean (SEM; mean ± SD). P values of less than 0.05 were considered statistically significant.

**RESULTS**

**Novel mutations in FZD4 and phenotypes:** In this study, four novel mutations in FZD4 (c.1188_1192del/p.F396fs, c.1220delC/p.A407Vfs*24, c.905G>A/p.C302Y, c.1325T>A/p.V442E) in the coding sequence were identified in four unrelated families. The Sorting Intolerant From Tolerant (SIFT) prediction and PolyPhen2 prediction of the two mutations (c.905G>A and c.1325T>A) are “damaging” and “probably damaging.” In accordance with the guidelines from the American College of Medical Genetics and Genomics (ACMG) [17], the mutation (c.1188_1192del/p.F396fs) was perceived as “likely pathogenetic,” and the mutation (c.1220delC/p.A407Vfs*24) was perceived as “pathogenetic.” These two missense mutations occurred at residues highly conserved across species (see the supplemental material). All mutations cosegregated with the disease phenotype of these four families (Figure 1) and were not detected in 200 healthy individuals. In this cohort, other mutations or polymorphisms, including c.757 C>T, c.542 G>A, c.313 A>G, c.400 G>T, c.1589 G>A, c.341 T>G, c.205 C>T, c.678 G>A, c.957 C>T, and c.660 G>A, were not detected.

**Figure 6. Analysis of mutations in FZD4 on its biological activity in the Norrin/β-catenin signaling pathway.**

A: SuperTopFlash (STF) cells/well were cotransfected with 700 ng DNA (200 ng of Norrin, 200 ng of LRP5, 100 ng of pSV-β-galactosidase control vector, and 200 ng of FZD4 [wild-type or mutation]) and 1.1 μl Lipofectamine 2000 transfection reagent. Forty-eight hours after transfection, the cells were harvested and washed twice with PBS. Luciferase activities were measured with a dual-luciferase assay kit. Reporter activity was normalized to the coexpressed β-galactosidase activity in each well. The positive control (LRP+/FZD4+/Norrin+) was normalized to 1. Each test was performed in triplicate. The reporter assay was repeated three times, and a representative result was obtained. Statistical analyses were performed with a two-tailed unpaired Student t test. B: Human embryonic kidney (HEK) 293 cells were transfected with 600 ng FLAG-FZD4 WT or mutant plasmids, respectively. Forty-eight hours post-transfection, cell lysates were immunoblotted (IB) with FLAG or actin. P, positive control. C: Protein quantification: the gray value of FLAG-FZD4/actin and normalized wild-type to 1 (1#: c.1188_1192del/p.F396fs, 2#: c.1220delC/p.A407Vfs; 3#: c.905G>A/p.C302Y; 4#: c.1325T>A/p.V442E).
c.1282_1286del, c.40_49del, c.1488 G>A, and c.1463 G>A, have been reported [10,18-26].

In family A, the carrier of the c.1188_1192del (p.F396fs) mutation was a 4-year-old boy. His right eye presented as total retinal detachment and a disappeared anterior chamber. However, only a peripheral avascular area was observed in his left eye (Figure 2A,B). His mutation-carrying father was asymptomatic with a peripheral avascular area and abnormal vessels in the left eye (Figure 2C–F). His mother had normal fundi (Figure 2F,H).

In family B, we identified the c.1220delC (p.A407Vfs*24) mutation in a 3-year-old boy and his affected father. The ocular presentation of the proband was extremely asymmetric. He exhibited a peripheral avascular area in the right eye and a falciform retinal fold in the left eye (Figure 3A,B). Angiography was not performed for the proband because of his parents’ unwillingness. His affected father had straightened vessels in the peripheral retina (Figure 3C,D). His mother had normal fundi (Figure 3E,F).

In family C, the c.905G>A (p.C302Y) mutation was identified in a 3-year-old boy and his affected father. The ocular presentation was also extremely asymmetric in this proband. The right fundus showed an avascular area and abnormal vessels in the peripheral retina. However, the left fundus manifested as similar to Norrie disease with choroidal atrophy (Figure 4A–D). Typical FEVR fundus changes were observed in his affected father (Figure 4E,F). His mother exhibited healthy retinal vasculature (Figure 4G,H).

In family D, we identified the c.1325T>A (p.V442E) mutation in a 2-year-old boy and his affected father. Fibrovascular tissue with retinal folds involving the macula was present in both eyes of the proband (Figure 5A,B). For his affected father, angiography revealed aberrant vessels and an avascular area in the peripheral retina (Figure 5C,D). His mother exhibited healthy retinal vasculature (Figure 5E,F).

**Luciferase reporter assay:** To verify the effect of the mutations in FZD4 on its biologic activity in the Norrin/β-catenin signaling pathway, we constructed the corresponding FZD4 mutant plasmids (c.1188_1192del, c.1220delC, c.905G>A, c.1325T>A) and analyzed the function of these mutant FZD4 proteins with a triplicate luciferase reporter assay. In the STF cells, we cotransfected LRP5/Norrin/FZD4 or other mutant FZD4 plasmids, respectively. After transfection, we checked the mRNA levels of the wild-type FZD4 and the four mutations, and we found the mRNA levels were comparable (Supplementary figure). We compared the luciferase activity to wild-type FZD4, and all four mutations in FZD4 induced variable reductions (17% for p.F396fs, 32% for p.A407Vfs, 11% for p.C302Y, and 39% for p.V442E) in the Wnt signaling (Figure 6A). These results suggested that these four mutations were pathogenic as they attenuated the activity of the Norrin/β-catenin signaling pathway. Next, we checked the protein level of the four mutations in FZD4 in the HEK 293 cells. We found that these mutations affected the stability of FZD4 (Figure 6B). Compared with the wild-type, the protein levels of the four mutants decreased by 10%, 37%, 56%, and 63%, respectively (Figure 6C).

**DISCUSSION**

In the present study, we identified four novel mutations in FZD4 in four families among 621 patients with FEVR but not in 200 healthy individuals. The typical FEVR phenotype was observed in all carriers. These results support the variable expressivity of FEVR, not only between family members but also between two eyes of an individual. These results indicate the complicated mechanism of FEVR.

FEVR is genetically heterogeneous and manifests a great variability of phenotypes. It has been reported that unrelated patients harboring the same mutation manifest the variable phenotype [27]. In the present study, three of the four probands exhibited extremely asymmetric phenotypes. One eye manifested mild fundus changes; however, the other eye exhibited advanced FEVR presentation, including total retinal detachment with a disappeared anterior chamber, similar to Norrie disease, and a facifold fold. For the four families, the parents harboring the same mutation were all asymptomatic with mild fundus changes. They were diagnosed with FEVR until angiography was performed. These results indicate that the prevalence rate of FEVR may be higher than expected in China. Thus, epidemiological investigation is suggested to investigate the prevalence rate in the so-called healthy population. Until now, the variability has remained unexplained. Further studies are needed to investigate the effects of the epigenetic effects or the presence of modifying genes in the variable phenotypes observed in unrelated patients harboring the same mutation or between two eyes of one individual.

LRP5 and FZD4, a coreceptor pair involved in the canonical Wnt signaling pathway, were identified with a positional screening approach [6,8]. Mutations in FZD4 can cause autosomal dominant FEVR [7,8,28]. In the present study, we identified four novel mutations in four unrelated families. The mutations were located at the transmembrane (p.F396fs; p.A407Vfs; p.V442E) or the topological domain (p.C302Y) of FZD4. Typical phenotypes were observed in all carriers. The complex genotype–phenotype correlation in FEVR remains unknown. Hayashi et al. found that a nonsense mutation in FZD4 completely abolished its signaling activity,
while single missense mutations in LRP5 and FZD4 caused a moderate level of reduction (ranging from 26% to 48%, 36% on average), and a double missense mutation in both genes caused a severe reduction in activity (71%). They observed the reduction in activity correlated roughly with the clinical phenotypes [27]. In the present study, the four novel mutations in FZD4 caused variable reductions in the Wnt signaling pathway, ranging from 11% to 39%. However, no correlation between the reduced luciferase activity and the clinical phenotype was observed in this study. The protein levels of the three mutations (p.F396fs; p.A407Vfs; p.V442E) correlated roughly with Wnt signaling activity. Interestingly, the Wnt signaling activity of the mutation p.C302Y was higher than that of the mutations p.F396fs and p.A407Vfs, but with a lower protein level. These results indicate that there might be other regulatory mechanisms and further demonstrated the complex disease-causing machinery of FEVR.

In summary, we identified four novel mutations in FZD4 in four unrelated families. Variability in clinical phenotypes was observed not only in the probands and parents harboring the same mutation but also between two eyes in the probands. These data further emphasize the complexity of FEVR-causing machinery. Future studies are necessary to investigate the disease-causing machinery. In addition, we suggest an epidemiological study to find asymptomatic patients with FEVR in the population and promote eugenics.

APPENDIX 1. STR ANALYSIS

To access the data, click or select the words “Appendix 1.”

ACKNOWLEDGMENTS

The authors thank the patients and family members for their participation in the study. The study was supported by National Natural Science Foundation of China (81470642, 81770964, 81770963); the Science and Technology Commission of Shanghai Municipality (15XD1502800). The authors declare no competing Interests. Author Contributions: Study conception and design: P.Z. Diagnosis of FEVR: P.Z. Data acquisition: T.T, X.Z. Function analysis: T.T, X.Z. Data interpretation: T.T. Manuscript preparation: T.T, X.Z, P.Z.

REFERENCES

1. Criswig VG, Schepens CL. Familial exudative vitreoretinopathy. Am J Ophthalmol 1969; 68:578-94. [PMID: 5394449].
2. Ober RR, Bird AC, Hamilton AM, Sehmi K. Autosomal dominant exudative vitreoretinopathy. Br J Ophthalmol 1980; 64:112-20. [PMID: 7362811].
3. Gilmour DF. Familial exudative vitreoretinopathy and related retinopathies. Eye (Lond) 2015; 29:1-14. [PMID: 25323851].
4. Canny CL, Oliver GL. Fluorescein angiographic findings in familial exudative vitreoretinopathy. Arch Ophthalmol 1976; 94:1114-20. [PMID: 947162].
5. Chen ZY, Battenelli EM, Fielder A, Bundey S, Sims K, Breakfield XO, Craig IW. A mutation in the Norrie disease gene (NDP) associated with X-linked familial exudative vitreoretinopathy. Nat Genet 1993; 5:180-3. [PMID: 8252044].
6. Robitaille J, MacDonald ML, Kaykas A, Sheldahl LC, Zeisler J, Dube MP, Zhang LH, Singaraja RR, Guernsey DL, Zheng B, Siebert LF, Hoskin-Mott A, Trese MT, Pimstone SN, Shastry BS, Moon RT, Hayden MR, Goldberg VP, Samuels ME. Mutant frizzled-4 disrupts retinal angiogenesis in familial exudative vitreoretinopathy. Nat Genet 2002; 32:326-30. [PMID: 12172548].
7. Jiao X, Venturto V, Trese MT, Shastry BS, Hejtmancik JF. Autosomal recessive familial exudative vitreoretinopathy is associated with mutations in LRP5. Am J Hum Genet 2004; 75:878-84. [PMID: 15346351].
8. Toomes C, Bottomley HM, Jackson RM, Towns KV, Scott S, Mackey DA, Craig JE, Jiang L, Yang Z, Trembath R, Woodruff G, Gregory-Evans CY, Gregory-Evans K, Parker MJ, Black GC, Downey LM, Zhang K, Inglehearn CF. Mutations in LRP5 or FZD4 underlie the common familial exudative vitreoretinopathy locus on chromosome 11q. Am J Hum Genet 2004; 74:721-30. [PMID: 15024691].
9. Poulter JA, Davidson AE, Ali M, Gilmour DF, Parry DA, Mintz-Hittner HA, Carr IM, Bottomley HM, Long VW, Downey LM, Sergouniotis PI, Wright GA, MacLaren RE, Moore AT, Webster AR, Inglehearn CF. Recessive mutations in TSPAN12 cause retinal dysplasia and severe familial exudative vitreoretinopathy (FEVR). Invest Ophthalmol Vis Sci 2012; 53:2873-9. [PMID: 22427576].
10. Salvo J, Lyubasyuk V, Xu M, Wang H, Wang F, Nguyen D, Wang K, Luo H, Wen C, Shi C, Lin D, Zhang K, Chen R. Next-generation sequencing and novel variant determination in a cohort of 92 familial exudative vitreoretinopathy patients. Invest Ophthalmol Vis Sci 2015; 56:1937-46. [PMID: 25711638].
11. Poulter JA, Ali M, Gilmour DF, Rice A, Kondo H, Hayashi K, Mackey DA, Kearns LS, Ruddle JB, Craig JE, Pierce EA, Downey LM, Mohamed MD, Markham AF, Inglehearn CF, Toomes C. Mutations in TSPAN12 Cause Autosomal-Dominant Familial Exudative Vitreoretinopathy. Am J Hum Genet 2016; 98:592-[PMID: 28863275].
12. Collin RW, Nikopoulos K, Dona M, Gilissen C, Hoischen A, Boonstra FN, Poulter JA, Kondo H, Berger W, Toomes C, Tahira T, Mohr LR, Blokland EA, Hettersonii L, Ali M, Groothuisink JM, Duijkers L, Inglehearn CF, Sollfrank L, Strom TM, Uchio E, van Nouhuys CE, Kremer H, Veltman JA, van Wijk E, vander Heijden SJ, van Nouhuys CE, Kremer H, Veltman JA, van Wijk E, Cremer FP. ZNF408 is mutated in familial exudative vitreoretinopathy and is crucial for the development of zebrafish retinal vasculature. Proc Natl Acad Sci USA 2013; 110:9856-61. [PMID: 23716654].
13. Robitaille JM, Gillett RM, LeBlanc MA, Gaston D, Nightingale M, Mackley MP, Parkash S, Hathaway J, Thomas A, Ellis A, Traboulsi EI, Heon E, Roy M, Shalev S, Fernandez CV, MacGillivray C, Wallace K, Fahiminiya S, Majewski J, McMaster CR, Bedard K. Phenotypic overlap between familial exudative vitreoretinopathy and microcephaly, lymphedema, and chorioretinal dysplasia caused by KIF11 mutations. JAMA Ophthalmol 2014; 132:1393-9. [PMID: 25124931].

14. Bhanot P, Brink M, Samos CH, Hsieh JC, Wang Y, Macke JP, Andrew D, Nathans J, Nusse R. A new member of the frizzled family from Drosophila functions as a Wingless receptor. Nature 1996; 382:225-30. [PMID: 8717036].

15. Moon RT, Kohn AD, De Ferrari GV, Kaykas A. WNT and beta-catenin signalling: diseases and therapies. Nat Rev Genet 2004; 5:691-701. [PMID: 15372092].

16. Xu Q, Wang Y, Dabhoub A, Smallwood PM, Williams J, Woods C, Kelley MW, Jiang L, Tasman W, Zhang K, Nathans J. Vascular development in the retina and inner ear: control by Norrin and Frizzled-4, a high-affinity ligand-receptor pair. Cell 2004; 116:883-95. [PMID: 15035989].

17. Richards S, Aziz N, Bale S, Bick D, Das S, Gastier-Foster J, Grody WW, Hegde M, Lyon E, Spector E, Voelkerding K, Rehm HL, Committee ALQA. Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. Genet Med 2015; 17:405-24.

18. Jia LY, Li XX, Yu WZ, Zeng WT, Liang C. Novel frizzled-4 gene mutations in chinese patients with familial exudative vitreoretinopathy. Arch Ophthalmol 2010; 128:1341-9. [PMID: 20938005].

19. Drenser KA, Dailey W, Vinekar A, Dalal K, Capone A Jr, Trese MT. Clinical presentation and genetic correlation of patients with mutations affecting the FZD4 gene. Arch Ophthalmol 2009; 127:1649-54. [PMID: 20008721].

20. Kondo H, Hayashi H, Oshima K, Tahira T, Hayashi K. Frizzled 4 gene (FZD4) mutations in patients with familial exudative vitreoretinopathy with variable expressivity. Br J Ophthalmol 2003; 87:1291-5. [PMID: 14507768].

21. Fei P, Zhu X, Jiang Z, Ma S, Li J, Zhang Q, Zhou Y, Xu Y, Tai Z, Zhang L, Huang L, Yang Z, Zhao P, Zhu X. Identification and functional analysis of novel FZD4 mutations in Han Chinese with familial exudative vitreoretinopathy. Sci Rep 2015; 5:16120-[PMID: 26530129].

22. Musada GR, Syed H, Jalali S, Chakrabarti S, Kaur I. Mutation spectrum of the FZD-4, TSPAN12 AND ZNF408 genes in Indian FEVR patients. BMC Ophthalmol 2016; 16:90-[PMID: 27316669].

23. Omoto S, Hayashi T, Kitahara K, Takeuchi T, Ueoka Y. Autosomal dominant familial exudative vitreoretinopathy in two Japanese families with FZD4 mutations (H69Y and C181R). Ophthalmic Genet 2004; 25:81-90. [PMID: 15370539].

24. Zhang K, Harada Y, Wei X, Shukla D, Rajendran A, Tawansy K, Bedell M, Lim S, Shaw PX, He X, Yang Z. An essential role of the cysteine-rich domain of FZD4 in Norrin/Wnt signaling and familial exudative vitreoretinopathy. J Biol Chem 2011; 286:10210-5. [PMID: 21177847].

25. Nikopoulos K, Venselaar H, Collin RW, Riveiro-Alvarez R, Boonstra FN, Hooymans JM, Mukhopadhyay A, Shears D, van Bers M, de Wijs J, van Essen AJ, Sijmons RH, Tilanus MA, van Nouhuys CE, Ayuso C, Hoefsloot LH, Cremers FP. Overview of the mutation spectrum in familial exudative vitreoretinopathy and Norrie disease with identification of 21 novel variants in FZD4, LRPS, and NDP. Hum Mutat 2010; 31:656-66. [PMID: 20340138].

26. Boonstra FN, van Nouhuys CE, Schuil J, van Wijs J, van der Donk KP, Nikopoulos K, Mukhopadhyay A, Scheffer H, Tilanus MA, Cremers FP, Hoefsloot LH. Clinical and molecular evaluation of probands and family members with familial exudative vitreoretinopathy. Invest Ophthalmol Vis Sci 2009; 50:4379-85. [PMID: 19324841].

27. Qin M, Kondo H, Tahira T, Hayashi K. Moderate reduction of Norrin signaling activity associated with the causative missense mutations identified in patients with familial exudative vitreoretinopathy. Hum Genet 2008; 122:615-23. [PMID: 17955262].

28. Downey LM, Bottomley HM, Sheridan E, Ahmed M, Gilmour DF, Ingleharn CF, Reddy A, Agrawal A, Bradbury J, Toomes C. Reduced bone mineral density and hyaloid vascular remnants in a consanguineous recessive FEVR family with a mutation in LRPS. Br J Ophthalmol 2006; 90:1163-7. [PMID: 16929062].